Latest Pharmaceutical Sector News

Wellnex Life has extended its licensing and supply agreement with Haleon UK for soft gel liquid paracetamol products until March 2027, reinforcing its position in the global analgesics market.

Algorae Pharmaceuticals has reached a key regulatory milestone as the TGA accepts its initial registration dossier, paving the way for potential commercialisation of its generic medicines in Australia and New Zealand.

CONNEQT Health reported a 40% revenue increase to $2.28 million for the half-year ending December 2025, driven by strong sales of its CONNEQT Pulse device and early subscription uptake. Despite narrowing its net loss by 14%, the company continues to navigate operational restructuring and funding challenges as it pivots towards a recurring revenue model.

Mayne Pharma has initiated legal proceedings against Cosette Pharmaceuticals and associated parties, seeking substantial damages following the collapse of their acquisition deal.

Botanix Pharmaceuticals has launched a A$45 million capital raising to support the expansion of its dermatology product Sofdra®, while negotiating to reduce active pharmaceutical ingredient costs by up to 40%. The raising includes a two-tranche placement and a security purchase plan, with options offered to investors.

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.

Unith Ltd reports a 17% rise in quarterly cash receipts alongside strategic funding and new technology launches, signalling momentum in its AI-driven digital human platform.

Resonance Health has reported record half-year revenue and strong progress in clinical trials, alongside promising new technology deployments set to enhance its global footprint.

Alpha HPA Limited reports strong progress on its HPA First Project Stage 2 construction and secures binding supply contracts for 2026 in the booming semiconductor sector, while launching a $225 million equity raise to fund expansion.

Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.

Way2VAT Ltd has reported a record quarterly revenue of A$2.13 million for Q4 FY25, driven by strong client growth and strategic acquisitions, setting the stage for further expansion in 2026.

Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.